Market Cap | 1.06B | P/E | - | EPS this Y | -88.90% | Ern Qtrly Grth | - |
Income | -260.32M | Forward P/E | -3.24 | EPS next Y | 1.50% | 50D Avg Chg | 16.00% |
Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -13.00% |
Dividend | N/A | Price/Book | 0.79 | EPS next 5Y | - | 52W High Chg | -64.00% |
Recommedations | 3.50 | Quick Ratio | 18.43 | Shares Outstanding | 487.70M | 52W Low Chg | 37.00% |
Insider Own | 11.14% | ROA | -13.79% | Shares Float | 320.30M | Beta | 0.48 |
Inst Own | 68.24% | ROE | -20.25% | Shares Shorted/Prior | 9.96M/13.37M | Price | 2.17 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 3,653,125 | Target Price | 2.10 |
Oper. Margin | - | Earnings Date | - | Volume | 63,258,845 | Change | 7.43% |
EQRx, Inc., a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. The company's clinical programs in pipeline includes Aumolertinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor for the treatment of patients with EGFR-mutated non-small cell lung cancer (NSCLC); Sugemalimab, is an anti-programmed cell death-ligand 1 (PD-L1) monoclonal antibody that treats stage III and stage IV NSCLC; and Lerociclib, a small molecule cyclin-dependent kinase 4/6 inhibitor, which has completed Phase 1 clinical trial in patients with metastatic breast cancer, as well as in combination with other targeted therapies for the treatment of patients with hormone receptor positive (HR+)/human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer. Its other programs in pipeline comprises clinical and pre-clinical, and discovery stage assets, such as Nofazinlimab, an anti-programmed death-1 (PD-1) antibody that is in Phase 3 trial for the treatment of patients with primary liver cancer, and for the treatment of patients with hepatocellular carcinoma; and EQ121, a selective Janus kinase-1 (JAK-1) inhibitor that has completed Phase 1 and in various Phase 1b and 2 trials in for the treatment of ankylosing spondylitis, atopic dermatitis, and rheumatoid arthritis. EQRx, Inc. was incorporated in 2019 and is headquartered in Cambridge, Massachusetts. As of November 9, 2023, EQRx, Inc. operates as a subsidiary of Revolution Medicines, Inc.
Goldman Sachs | Neutral | May 10, 23 |
JP Morgan | Underweight | Nov 14, 22 |
Goldman Sachs | Neutral | Nov 11, 22 |
Jefferies | Hold | Nov 11, 22 |
JP Morgan | Neutral | Aug 16, 22 |
Goldman Sachs | Buy | Jun 13, 22 |
Cowen & Co. | Outperform | Apr 22, 22 |
Jefferies | Buy | Mar 18, 22 |